Rhys D R Evans1, James H Lan1,2,3, Matthew Kadatz1,2, Sandeep Brar1, Doris T Chang4, Lachlan McMichael1, Jagbir Gill3,4,5,6, John S Gill7,4,8. 1. Division of Nephrology, Kidney Transplant Program, University of British Columbia, Vancouver, British Columbia, Canada. 2. Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada. 3. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. 4. Providence Health Research Institute, Vancouver, British Columbia, Canada. 5. Centre for Health Evaluation and Outcomes Sciences, Vancouver, British Columbia, Canada. 6. University of British Columbia School of Population and Public Health, Vancouver, British Columbia, Canada. 7. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada jgill@providencehealth.bc.ca. 8. Department of Nephrology, Tufts-New England Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND AND OBJECTIVES: The optimal induction treatment in low-immune risk kidney transplant recipients is uncertain. We therefore investigated the use and outcomes of induction immunosuppression in a low-risk cohort of patients who were well matched with their donor at HLA-A, -B, -DR, -DQB1 on the basis of serologic typing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study was an observational study of first adult kidney-only transplant recipients in the United States recorded by the Organ Procurement and Transplant Network. RESULTS: Among 2976 recipients, 57% were treated with T cell-depleting antibodies, 28% were treated with an IL-2 receptor antagonist, and 15% were treated without induction. There was no difference in allograft survival, death-censored graft survival, or death with function between patients treated with an IL-2 receptor antagonist and no induction therapy. In multivariable models, patients treated with T cell-depleting therapy had a similar risk of graft loss from any cause, including death (hazard ratio, 1.19; 95% confidence interval, 0.98 to 1.45), compared with patients treated with an IL-2 receptor antagonist or no induction. The findings were consistent in subgroup analyses of Black recipients, patients grouped by calculated panel reactive antibody, and donor source. The incidence of acute rejection at 1 year was low (≤5%) and did not vary between treatment groups. CONCLUSIONS: Use of induction therapy with T cell-depleting therapy or IL-2 receptor antagonists in first kidney transplant recipients who are well matched with their donor at the HLA-A, -B, -DR, -DQB1 gene loci is not associated with improved post-transplant outcomes.
BACKGROUND AND OBJECTIVES: The optimal induction treatment in low-immune risk kidney transplant recipients is uncertain. We therefore investigated the use and outcomes of induction immunosuppression in a low-risk cohort of patients who were well matched with their donor at HLA-A, -B, -DR, -DQB1 on the basis of serologic typing. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our study was an observational study of first adult kidney-only transplant recipients in the United States recorded by the Organ Procurement and Transplant Network. RESULTS: Among 2976 recipients, 57% were treated with T cell-depleting antibodies, 28% were treated with an IL-2 receptor antagonist, and 15% were treated without induction. There was no difference in allograft survival, death-censored graft survival, or death with function between patients treated with an IL-2 receptor antagonist and no induction therapy. In multivariable models, patients treated with T cell-depleting therapy had a similar risk of graft loss from any cause, including death (hazard ratio, 1.19; 95% confidence interval, 0.98 to 1.45), compared with patients treated with an IL-2 receptor antagonist or no induction. The findings were consistent in subgroup analyses of Black recipients, patients grouped by calculated panel reactive antibody, and donor source. The incidence of acute rejection at 1 year was low (≤5%) and did not vary between treatment groups. CONCLUSIONS: Use of induction therapy with T cell-depleting therapy or IL-2 receptor antagonists in first kidney transplant recipients who are well matched with their donor at the HLA-A, -B, -DR, -DQB1 gene loci is not associated with improved post-transplant outcomes.
Authors: P-Y Fan; V B Ashby; D S Fuller; L E Boulware; A Kao; S P Norman; H B Randall; C Young; J D Kalbfleisch; A B Leichtman Journal: Am J Transplant Date: 2010-04 Impact factor: 8.086
Authors: C Ponticelli; A Yussim; V Cambi; C Legendre; G Rizzo; M Salvadori; D Kahn; H Kashi; K Salmela; L Fricke; U Heemann; J Garcia-Martinez; R Lechler; H Prestele; D Girault Journal: Transplantation Date: 2001-10-15 Impact factor: 4.939
Authors: Panduranga S Rao; Douglas E Schaubel; Mary K Guidinger; Kenneth A Andreoni; Robert A Wolfe; Robert M Merion; Friedrich K Port; Randall S Sung Journal: Transplantation Date: 2009-07-27 Impact factor: 4.939
Authors: Bekir Tanriover; Vishal Jaikaransingh; Malcolm P MacConmara; Justin R Parekh; Swee-Ling Levea; Venkatesh K Ariyamuthu; Song Zhang; Ang Gao; Mehmet U S Ayvaci; Burhaneddin Sandikci; Nilum Rajora; Vaqar Ahmed; Christopher Y Lu; Sumit Mohan; Miguel A Vazquez Journal: Clin J Am Soc Nephrol Date: 2016-06-30 Impact factor: 8.237
Authors: Vikas R Dharnidharka; Abhijit S Naik; David A Axelrod; Mark A Schnitzler; Zidong Zhang; Sunjae Bae; Dorry L Segev; Daniel C Brennan; Tarek Alhamad; Rosemary Ouseph; Ngan N Lam; Mustafa Nazzal; Henry Randall; Bertram L Kasiske; Mara McAdams-Demarco; Krista L Lentine Journal: Transpl Int Date: 2017-11-02 Impact factor: 3.782
Authors: A Hart; J M Smith; M A Skeans; S K Gustafson; A R Wilk; S Castro; J Foutz; J L Wainright; J J Snyder; B L Kasiske; A K Israni Journal: Am J Transplant Date: 2020-01 Impact factor: 8.086